Group 1 - The application for Dapoxetine α injection by Terumo Corporation, Kofu Factory has been accepted by the National Medical Products Administration on January 5, 2026, with acceptance number JTS2600001 [1] - The drug Dapoxetine α injection is classified as a biological product and is under the import registration application type [1] - The companies involved in the application include Terumo Corporation, Kofu Factory, Kyowa Kirin Co., Ltd., and North China Pharmaceutical Jintan Biotechnology Co., Ltd. [1] Group 2 - North China Pharmaceutical Jintan Biotechnology Co., Ltd. was established on April 2, 2002, and is a medium-sized company with 619 insured employees [1] - The registered capital of North China Pharmaceutical Jintan Biotechnology Co., Ltd. is 1.85051637 billion RMB, with a paid-in capital of 1.63989152 billion RMB [1] - The major shareholder is North China Pharmaceutical Co., Ltd., holding 98% of the shares, while North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. holds 2% [1]

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at promoting high-quality development and enhancing investment value, particularly for small and medium-sized investors [1][3]. Group 1: Business Focus and Strategy - The company focuses on its core business of pharmaceutical product research, production, and sales, emphasizing quality and human health as its mission [1]. - The company aims to enhance operational quality by improving existing business areas and exploring new growth through innovation and collaboration [2][5]. Group 2: Shareholder Returns - The company has established a three-year shareholder return plan (2023-2025), prioritizing cash profit distribution, with a commitment to distribute at least 30% of the average annual distributable profit over the three years [3][4]. - Cumulative cash dividends over the last three accounting years amounted to 68.63 million yuan, exceeding the planned return requirements [3]. Group 3: Technological Innovation - The company has invested approximately 3.7 billion yuan in R&D since 2022, with an annual average R&D investment increase of 108.78% from 2019 to 2021 [5]. - Significant breakthroughs in technology include the approval of a new drug and multiple product launches, demonstrating the company's commitment to innovation [5][6]. Group 4: Investor Relations Management - The company emphasizes effective communication with investors through various channels, ensuring transparency and timely updates on company developments [7][8]. - Regular performance briefings and investor education activities are conducted to enhance investor understanding and protect their rights [7]. Group 5: Corporate Governance - The company adheres to relevant laws and regulations, continuously improving its governance structure and internal control systems to enhance operational standards [9][10]. - A new committee structure has been established to strengthen decision-making and oversight, ensuring fair treatment of all shareholders [10][11].

Core Viewpoint - North China Pharmaceutical has announced a "Quality Improvement and Efficiency Enhancement Return" action plan aimed at enhancing operational quality, shareholder returns, and fostering technological innovation [1] Group 1: Action Plan Highlights - The company will focus on its core business to improve operational quality [1] - Emphasis will be placed on shareholder returns, with a commitment to distribute no less than 30% of annual distributable profits as cash dividends [1] - The plan includes strengthening investor relations management to enhance value transmission [1] Group 2: Financial Commitments - Over the past three years, the company has distributed a total of 68.6292 million yuan in dividends [1] - Cumulative investment in research and development over three years amounts to approximately 3.7 billion yuan [1] Group 3: Governance and Management - The company aims to improve governance standards and operational compliance [1] - There will be a focus on managing the "key minority" to solidify responsibility in performance [1]

华北制药股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻党的二十大和中央金融工作会议精神，落实国务院《关于 进一步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于 开展沪市公司"提质增效重回报"专项行动的倡议》，推动公司高质量发 展和投资价值提升，保护投资者尤其是中小投资者合法权益，华北制药股 份有限公司（以下简称"公司"）结合公司战略规划及自身实际经营情况， 制定了"提质增效重回报"行动方案。本次行动方案已于 2025 年 12 月 29 日经公司第十一届董事会第二十六次会议审议通过，具体方案如下： 一、聚焦主责主业，提升经营质量 公司主要从事医药产品的研发、生产和销售等业务，产品涉及化学制 药、现代生物技术药物、维生素及健康消费品、生物农兽药等领域。公司 始终秉持"人类健康至上，质量永远第一"的企业宗旨，以"一切为了人 类健康"为企业使命，努力打造国内领先、国际一流的医药健康产业集团， 建设美丽新华药。 近年来，公司以党的建设为统领，"稳中求进"为总基 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-065 表决结果：同意 10 票； 反对 0 票； 弃权 0 票。 特此公告。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 六次会议于 2025 年 12 月 26 日向全体董事及公司高级管理人员以电子邮件 形式发出会议通知，以通讯方式于 2025 年 12 月 29 日召开。本次会议应出 席董事 10 名，实际出席董事 10 名。会议的召集、召开和表决程序符合《公 司法》等法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《关于制定"提质增效重回报"行动方案的议案》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《关于"提质增效重回报"行动方 案的公告》。 华北制药股份有限公司 第十一届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华北制 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Summary of Key Points Core Viewpoint - As of December 18, the margin financing and securities lending balance in the Shanghai and Shenzhen markets decreased to 24,916.5 billion yuan, reflecting a reduction of 34.69 billion yuan from the previous trading day [1]. Group 1: Market Overview - The financing balance stands at 24,748.41 billion yuan, down by 33.13 billion yuan compared to the previous trading day [1]. - The Shanghai market's margin balance is 12,666.44 billion yuan, decreasing by 43.7 billion yuan, while the Shenzhen market's balance is 12,250.06 billion yuan, increasing by 9.01 billion yuan [1]. Group 2: Stock Performance - A total of 1,604 stocks experienced net buying of margin funds, with 60 stocks having net buying amounts exceeding 10% of their total trading volume [3]. - The top three stocks by net buying ratio are: - Hotway Co., Ltd. (24.35%) - Xinhongye (23.16%) - Saitex New Materials (23.13%) [4][5]. Group 3: Significant Net Buying Stocks - There are 29 stocks with net buying amounts exceeding 100 million yuan, with the top three being: - Xinyi Sheng (609 million yuan) - China Ping An (516 million yuan) - China Satellite (278 million yuan) [7].

Meeting Overview - The first extraordinary general meeting of shareholders was held on December 15, 2025, at the company's conference room in Shijiazhuang [2] - The meeting was conducted with a combination of on-site and online voting, presided over by Mr. Wang Lixin [2][3] Attendance - Out of 9 current directors, 8 attended the meeting, with Mr. Wang Xiujun absent due to work reasons [3] - Out of 5 current supervisors, only 1 attended, with others absent for work reasons [3] - The company secretary and other senior management personnel were present [3] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board and amendment of the Articles of Association [4] 2. Revision of the Rules of Procedure for Shareholders' Meetings [4] 3. Revision of the Rules of Procedure for Board Meetings [4] 4. Revision of the Related Party Transaction Management System [4] - All resolutions received more than two-thirds of the valid voting rights [5] Legal Verification - The meeting was witnessed by Beijing DeHeng Law Firm, confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [6] Board Meeting Overview - The 25th meeting of the 11th Board of Directors was held on December 15, 2025, with all 10 directors present [9] - The meeting was convened in accordance with legal and regulatory requirements [9] Board Resolutions - The following resolutions were passed: 1. Election of Mr. Zhang Min as the Vice Chairman of the 11th Board of Directors, effective immediately [10] 2. Adjustment of the members of the Board's Strategy (Investment Decision) and Sustainable Development Committee, with Mr. Zhang Min elected and Mr. Xiao Zhiguang stepping down [12] - All resolutions received unanimous approval [13]

Group 1 - The company announced the approval of the election of the vice chairman of the board during the 25th meeting of the 11th board of directors [2] - The company also approved the adjustment of the members of the Strategic (Investment Decision) and Sustainable Development Committee of the board [2]

Group 1 - The core point of the article is that North China Pharmaceutical announced the approval of several resolutions at its first extraordinary general meeting of shareholders in 2025, including the cancellation of the supervisory board and amendments to related proposals [2] Group 2 - The company held its first extraordinary general meeting of shareholders on December 15 [2] - The resolutions passed include the cancellation of the supervisory board and amendments to various proposals [2]